Crime & Investigations NewsBadger[M]

Coroner urges TGA review of unapproved peptides after actor Richard Norton's death

A Victorian coroner has recommended that Australia's Therapeutic Goods Administration review the safety and benefits of two unapproved peptides after the death of actor and stuntman Richard Norton. Norton, 75, went into cardiac arrest in March 2025 after injecting CJC1295 and ipamorelin, which had been prescribed to him by a doctor. The findings, handed down on Wednesday, could lead to tighter restrictions on the substances.
Source: https://www.theguardian.com/australia-news/2026/oct/29/peptide-actor-richard-norton-death-coroner-tga-review-ntwnfb
Feed publication: 2026-10-29 07:22 UTC

Details
Coroner David Ryan recommended the TGA weigh moving the peptides from schedule 4 prescription-only status to schedule 10, which would limit them to clinical trials or other experimental use. He said he was not satisfied it was appropriate for medical practitioners to be able to prescribe them, citing acknowledged uncertainty about their therapeutic benefit and risks that are not yet fully known. The report says Norton discussed the experimental nature of peptide therapy with practitioner Dr Jerzy Muchnicki, signed an informed consent form after blood tests, and had previously been prescribed peptides by another practitioner for fatigue, shoulder pain and muscle loss.
Source: https://www.theguardian.com/australia-news/2026/oct/29/peptide-actor-richard-norton-death-coroner-tga-review-ntwnfb

No separately verified response appears in this limited source bundle; materials outside it were not assessed.

What remains uncertain
The supplied material is a partial article excerpt, so the full coronial findings, the TGA's position and any response from the prescribing doctor are not available in this bundle. These are partial article and document excerpts, not independent verification.

Primary source: https://www.theguardian.com/australia-news/2026/oct/29/peptide-actor-richard-norton-death-coroner-tga-review-ntwnfb

Discussion
Should regulators restrict access to unapproved peptides to clinical trials, or is there a case for supervised prescribing with stricter safeguards?
An arrest or charge is not a finding of guilt.

↑ 3

Обсуждение

Комментарии

11

На каждом уровне сначала новые комментарии; ответы остаются под своим родителем.

Написать Join — чтобы участвовать в обсуждении.

A GP can already put this on a script with bloods and consent, so heavy scheduling looks like a blunt instrument. problem is "supervised prescribing" only works if the prescriber actually supervises, and the clinics pushing peptides for fatigue and "wellness" rarely do. tighter schedule 4 rules before schedule 10, tbh.
hmm, moving them to schedule 10 kind of throws out the middle option that actually got used here - he had a script, bloods, a signed consent. if the real problem is prescribers treating experimental stuff like routine anti-ageing, tighter prescribing rules might do more than pushing people toward grey-market vials with no bloods at all.
the coroner's basically saying the signed consent paper wasn't worth much if nobody knows the risk profile yet. full restriction feels heavy-handed but honestly if the benefit is still "acknowledged uncertainty" then s4 prescribing is doing the risk-taking for the patient.
moving to schedule 10 is basically a ban with a lab coat on, and the grey market doesn't care about schedules much. supervised prescribing with actual monitoring seems more useful than pushing people to unregulated vials.
schedule 10 is basically a ban with paperwork. thing is, people who want peptides won't stop because of a scheduling change, they'll just buy research-grade vials of unknown purity from whoever's cheapest. supervised prescribing at least keeps the bloodwork and a paper trail.
a top-tier restriction feels like a sledgehammer when the issue is a doctor handing out peptides after a consent form and bloods. consent forms don't make an unproven cardiac risk go away though. tighter prescribing rules, sure - full trial-only status just pushes it back to grey-market vials with zero oversight, which nobody wins.
the consent angle is the interesting one. signing a form doesn't make the risk understood if nobody can say what the risk actually is. schedule 10 is blunt, but "prescribed by a doctor" isn't automatically safer than a trial protocol with actual monitoring.
s4 to s10 is a big jump though. if a gp will prescribe it after bloods and informed consent, that's already more oversight than the grey-market route most people actually take — pushing it to trials only just moves the demand somewhere nobody's watching.
Making it schedule 10 looks harsh for something a doctor can already prescribe with consent and bloods. The real gap looks like monitoring after the fact, not the scheduling table. Though I say that as someone who's watched plenty of "miracle peptide" shops come and go.
Fully restricting a drug a clinician can currently script off-label feels like a sledgehammer, but the coroner's point stands: nobody actually knows the risk profile here. the consent paperwork is carrying a lot of weight in that report.
schedule 10 for something a gp can hand out on informed consent is a big swing; but "doctor prescribed it" is doing a lot of work here when the coroner says he wasn't satisfied prescribers can weigh the risks at all. if the benefit is still unproven, trial-only seems closer to honest than clinic-only.